

# Press Releases

## Boston Scientific Reports Key Data at the 35th Annual Scientific Sessions of the Heart Rhythm Society

### Broad Set of Data Reinforces Commitment to Advancing Research and Technology in Electrophysiology

---

May 5, 2014

NATICK, Mass., May 5, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will be presenting new data at the 35<sup>th</sup> Annual Scientific Sessions of the Heart Rhythm Society in San Francisco on May 7-10, highlighting the company's commitment in the field of electrophysiology. Sixteen clinical presentations, including two late-breaking clinical trials, will provide insights into Boston Scientific research in cardiovascular disease, including atrial fibrillation and sudden cardiac arrest, helping to create new opportunities to improve the lives of patients.

#### Schedule of Events

All programs are Pacific Time, with events held at the Moscone Convention Center unless otherwise noted.

#### Wednesday, May 7

- **Complications Associated with the Totally Subcutaneous Implantable Defibrillator:**

Bradley Knight, M.D., of Northwestern University will provide an overview of results from a pooled analysis of 882 S-ICD System patients from the IDE Study and EFFORTLESS Registry in this poster presentation (P001-53) at 6:00 p.m. in the Exhibit Hall.

- **26th Annual Michel Mirowski Sudden Cardiac Arrest Symposium and Award Presentation.**

The company will sponsor the 26th Annual Michel Mirowski Sudden Cardiac Arrest Symposium and Award Presentation from 7:00 p.m. to 9:30 p.m. in the Yerba Buena Ballroom (Salon 7) of the San Francisco Marriott Marquis. Moderated by last year's award recipient, Karl-Heinz Kuck, M.D., the event will begin with opening remarks by Chief Medical Officer Kenneth Stein, M.D., followed by recognition of past award recipients, as well as the legacy of Michel Mirowski, M.D. The ceremony will then honor

this year's Mirowski Award recipient, Michael R. Rosen, M.D. Three presentations led by Vivek Reddy, M.D., Michael Gold, M.D., and Michael R. Rosen, M.D., will focus on recent evolutions in the world of electrophysiology and the development of novel technologies related to biological pacing, left atrial appendage closure and defibrillation.

## Thursday, May 8

- **Left Atrial Appendage Closure: Why do we need an alternative to long-term warfarin therapy for patients with non-valvular atrial fibrillation?**

Vivek Reddy, M.D., of Mt. Sinai Hospital and Shephal Doshi, M.D., of St. John's Health Center will present perspectives from 9:35a.m. to 10:30 a.m. PT in the Rhythm Theatre #2 in the Exhibit Hall.

- **Selecting the Best ICD For Your Patient: Subcutaneous or Transvenous**

Michael Gold, M.D., of Medical University of South Carolina and Jeanne Poole, M.D., of University of Washington will present perspectives in this presentation held from 12:15 p.m. to 1:15 p.m. in Rhythm Theatre #2 in the Exhibit Hall.

- **Shockless Implant Evaluation (SIMPLE): A Randomized Trial of Routine Defibrillation Testing, Compared to No Testing, at Time of Defibrillator Implantation (Late-Breaking Clinical Trial)**

Jeffery S. Healey, M.D., of Population Health Research Institute will present the findings as a late-breaking clinical trial (LB01-01) at 1:30 p.m. in Room 305, Moscone South.

- **Outcomes in Patients Receiving a Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD): IDE Trial Results at Twenty-two Months**

Angel Leon, M.D., of Emory University will present the findings during an oral presentation (AB06-01) at 1:30 p.m. in Room 2018, Moscone West.

- **Safety of the S-ICD in Patients after Transvenous ICD Infection: Long-term Follow-up in the IDE and EFFORTLESS Trial**

Lucas Boersma, M.D., of St. Antonius Ziekenhuis will present findings during an oral presentation (AB06-02) at 1:45 p.m. in Room 2018, Moscone West.

- **Combined Analysis of Subcutaneous ICD Outcomes in Hypertrophic Cardiomyopathy Patients from the EFFORTLESS Registry & IDE Study**

Pier Lambiase, M.D., of The Heart Hospital will provide an overview of results in an oral presentation (AB06-06) at 3:15 p.m. in Room 2018, Moscone West.

- **Mini-Electrode Morphology and Pace-Capture for Radiofrequency Ablation Lesion Assessment**

Chirag Barbhaya, M.D., of Brigham and Women's Hospital will present perspectives during a poster presentation (P003-110) at 3:30 p.m. in the Exhibit Hall.

- **Determinants of Tissue Contact Using the 8mm Equipped with Mini Electrode Technology**

Boaz Avitall, M.D., of University of Illinois will present findings during this poster presentation (P003-94) at 3:30 p.m. in the Exhibit Hall.

## Friday, May 9

- **Mapping of Ventricular Scar with 0.8mm Mini-Electrodes Facilitates Identification of Potentially Arrhythmogenic Areas Not Identified with a 4mm Electrode**

Leon M. Ptaszek, M.D., of Massachusetts General Hospital will present findings during this poster presentation (P004-131) at 9:30 a.m. in the Exhibit Hall.

- **Connecting the Dots: A novel ablation technique for the creation of contiguous linear lesion**

Boaz Avitall, M.D., of University of Illinois will present perspectives during this poster presentation (P004-88) at 9:30 a.m. in the Exhibit Hall.

- **Incidence and Efficacy of Shocks with the S-ICD: Pooled Long-term Results from the IDE and EFFORTLESS Studies**

Michael Gold, M.D., of Medical University of South Carolina will present perspectives during this oral presentation (AB28-01) at 2:30 p.m. in Room 2020, Moscone West.

- **A Novel Simple Predictor of Mortality Risk in ICD and CRT-D Patients: The heart rate score**

Bruce Wilkoff, M.D., of Cleveland Clinic will present results during this poster presentation (PO05-141) at 2:00 p.m. in the Exhibit Hall.

- **Heart Rate Score Predicts Which CRT-D Patients Benefit from Survival from DDDR Pacing in CRT-D Patients: Results from ALTITUDE**

Brian Olshansky, M.D., of University of Iowa Hospital and Clinics will present perspectives during this oral presentation (AB29-04) at 2:15 p.m. in Room 2024, Moscone West.

- **Heart Rate Score, an Easy and Intuitive Measure of Chronotropic Incompetence in Device Patients**

Mark Richards, M.D., of Northwest Ohio Cardiology Consultants will present findings in this oral presentation (AB29-05) at 2:30 p.m. in Room 2024, Moscone West.

## Saturday, May 10

- **Use of Remote Monitoring is Associated with Improved Outcomes Among Patients with Implantable Cardioverter Defibrillators (Late-Breaking Clinical Trial)**

Joseph G. Akar, M.D., of Yale University will present the findings as a late-breaking clinical trial (LB03-03) at 11:00 a.m. in Room 2004, Moscone West.

In addition, two independent studies will be presented at the congress that highlight Boston Scientific ICD and CRD device longevity:

## Thursday, May 8

- **Independent study: Device Longevity in Cardiac Resynchronization Therapy Implantable Cardioverter Defibrillators Differs Between Manufacturers**

Jens B. Johansen, M.D., of Odense University Hospital will present findings from the study in this featured poster presentation (MP01-04) at 10:00 a.m. in the Exhibit Hall.

## Friday, May 9

- **Independent study: Longevity of Cardiac Resynchronization Defibrillators: A multicenter registry study**

Robert Hauser, M.D., of Minneapolis Heart Institute Foundation will present findings during this poster presentation (AB39-05) at 1:30 p.m. in Room 2010, Moscone West.

All clinical data results are embargoed until the time of each scientific presentation. Conference attendees are invited to visit Boston Scientific at booth #1602.

## **About Boston Scientific**

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit [www.bostonscientific.com](http://www.bostonscientific.com) and connect on [Twitter](#) and [Facebook](#).

## **Cautionary Statement Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding markets for our products, our business plans, presentations, clinical trials and impact of data, product performance and impact, and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

**CONTACT:**

Nisha Deo

408-893-9243 (cell)

Corporate Affairs & Communications

Boston Scientific Corporation

[nisha.deo@bsci.com](mailto:nisha.deo@bsci.com)

Susie Lisa, CFA

508-652-5345 (office)

Investor Relations

Boston Scientific Corporation

[investor\\_relations@bsci.com](mailto:investor_relations@bsci.com)

SOURCE Boston Scientific Corporation

